University College London innovators and eXmoor strengthen academic-to-clinic gene therapy path

eXmoor Pharma, the UK’s only fully integrated cell and gene therapy CDMO with embedded consultancy expertise, and the Translational Research Office (TRO) at University College London (UCL) have formed a strategic collaboration to accelerate the development of novel cell and gene therapies (CGTs) from academic research into clinical application.

The collaboration will support earlier and more efficient engagement between UCL innovators and eXmoor’s multidisciplinary teams, helping to reduce the risk, cost and complexity of technology development. By combining the TRO’s translational research expertise with eXmoor’s consultancy, development and Good Manufacturing Practice (GMP) capabilities, the collaboration aims to create faster and more effective routes to clinical trial readiness and beyond.

A shared focus on strategic, scalable translation

UCL and eXmoor share a commitment to overcoming the technical and regulatory challenges that often delay promising CGT candidates. Through this relationship, academic teams will gain early access to:

• CMC consulting and regulatory strategy support
• Laboratory capacity and expertise in process and analytical development
• GMP manufacturing for early clinical studies
• Cross-modality insight across viral vectors, autologous and allogeneic cell therapies, and RNA technologies

Through this collaboration, UCL researchers will benefit from structured early engagement with eXmoor’s expert teams, which will help shape more practical and commercially aware development strategies. This includes opportunities for grant input, regular consultancy clinics, and joint events, all designed to bridge the gap between academic innovation and GMP readiness.

eXmoor will benefit from direct collaboration with UCL’s translational researchers, enabling its teams to stay at the forefront of technological innovation and evolving CGT modalities. By working together from the earliest stages of development, eXmoor can align its capabilities with emerging innovations and foster scalable, GMP-ready solutions that reflect real clinical and commercial potential